PDCD1 and non-small cell lung carcinoma: PD-1 blockade monotherapy yielded an objective response rate (ORR) of approximately 20%, a median progression-free survival (PFS) of 3–6 months, and a median overall survival (OS) of 10–15 months as subsequent-line therapy among patients with previously treated NSCLC [13].